天演药业上涨11.73%，报2.19美元/股，总市值1.03亿美元

Core Viewpoint - Tianyan Pharmaceuticals (ADAG) experienced a significant stock price increase of 11.73%, reaching $2.19 per share, with a total market capitalization of $103 million as of August 20 [1] Financial Performance - As of December 31, 2024, Tianyan Pharmaceuticals reported total revenue of $103,200, a year-over-year decrease of 99.43% [1] - The company recorded a net loss attributable to shareholders of $33.42 million, reflecting a year-over-year decline of 76.41% [1] Company Overview - Tianyan Pharmaceuticals is a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker ADAG, focused on discovering and developing novel cancer immunotherapies based on original antibodies [1] - The company utilizes a powerful platform that combines computational biology and artificial intelligence to develop new antibodies with high safety and efficacy, aiming to benefit more cancer patients [1] - The company's antibody discovery engine, known as the "Dynamic Precision Library," is driving the development of its product pipeline, with the goal of creating potentially innovative or best-in-class products globally [1]